4695 Chabot Dr. Ste. 200-265 Pleasanton
7 articles about Amador BioSciences
Amador Bioscience Welcomes Dr. Lorin Roskos as Chief Scientific Officer and President of Quantitative Clinical Pharmacology
Amador Bioscience has announced the appointment of Dr. Lorin Roskos as Chief Scientific Officer (CSO) and President of Quantitative Clinical Pharmacology (QCP).
Dr. Lorin K Roskos, Biopharmaceutical Leader and Executive, Joins Amador Bioscience's Board of Directors
Amador Bioscience, a full-service CRO with global expertise in translational research and clinical development, announces the appointment of Lorin K Roskos, PhD, to its board of directors, effective immediately.
Dr. Nidal Huniti joins A2PG as President
A2PG and Amador Bioscience announced that Dr. Nidal Huniti has joined the company as President of A2PG.
Here's who rang in the New Year by joining the NASDAQ or raising private equity funds.
Amador Bioscience Announces the Completion of $60 Million Series B+ Round Financing
Amador Bioscience announced today that it has completed 60MM USD Series B+ financing led by MSA Capital, a global private equity firm .
Amador Bioscience completed the acquisition of Ann Arbor Pharmacometrics Group (A2PG)
Amador Bioscience announced today that it has completed the acquisition of Ann Arbor Pharmacometrics Group ( A2PG), a premier pharmacometrics consulting firm based in Ann Arbor, Michigan.
Institutional Investors Co-Led Series B Financing of Amador Bioscience, a Global Translational Sciences and Clinical Pharmacology CRO
Amador Bioscience, a contract research organization that provides global-standard translational sciences and clinical pharmacology services to leading biopharmaceutical companies, announced the completion of Series B financing to support its further global expansion.